UKCA marking for medical devices: MHRA registration and the route to Great Britain
What UKCA marking requires for medical devices, how MHRA registration and UK Responsible Person duties work, and how the Great Britain route differs from EU MDR.
Placing a medical device on the Great Britain market is a separate exercise from CE marking. The rules are close enough to feel familiar and different enough to catch teams out.
The legal frame
Great Britain — England, Wales and Scotland — is governed by the UK Medical Devices Regulations 2002, which are based on the older EU directives rather than EU MDR. Northern Ireland follows the EU rules under separate arrangements, so a single "UK" plan is usually two plans.
Conformity is shown by UKCA marking, assessed where required by a UK Approved Body. MHRA has accepted CE-marked devices for the GB market under time-limited arrangements; those acceptance windows have shifted more than once, so confirm the current dates against MHRA guidance before building a timeline around them.
MHRA registration and the UK Responsible Person
All medical devices placed on the GB market must be registered with MHRA. A manufacturer without a UK place of business must appoint a UK Responsible Person, established in the UK, who registers the devices and acts as the point of contact for MHRA, holds access to the technical documentation, and cooperates on vigilance and corrective actions.
Registration is per device and per class, and it is an ongoing duty: changes to devices, classes or the Responsible Person have to be reflected.
Where GB and EU diverge
Classification under the UK regulations follows the directive-era rules, so a device pushed into a higher class by EU MDR Rule 11 may classify differently for GB. Labelling, declaration of conformity and Approved Body identification numbers differ. Post-market surveillance and vigilance reporting go to MHRA on MHRA timelines.
The practical implication is that evidence can usually be reused, but documentation, marking and registration cannot simply be copied across.
Planning sequence
Decide GB market timing relative to EU. Confirm the current CE acceptance position with MHRA guidance. Establish the UK Responsible Person before you need registration, not after. Then map the technical documentation you already hold against UK requirements and close the gaps.
How DevicePath helps
DevicePath gives high-level UK (UKCA / MHRA) considerations together with EU MDR notes, FDA class, product codes, premarket pathway and 510(k) predicate candidates — from a plain-language description of the device. It is open source and built to give small teams a defensible starting point in seconds.